NCT04936841 - Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 5, 2021

Primary Completion Date

October 4, 2022

Study Completion Date

October 4, 2022

Conditions

Head and Neck Cancer

Interventions

DRUG

NKTR-214

Bempegaldesleukin (NKTR-214) is an immunotherapeutic protein prodrug specifically designed to activate the patient's immune system for the treatment of cancer by providing a controlled, sustained signal to the interleukin-2 (IL-2) receptor pathway (pharmacological classification: immunostimulatory interleukin cytokine)

DRUG

anti-PD-1 therapy

immunotherapy drug, monoclonal antibody

RADIATION

Palliative Radiation

radiation to relieve symptoms

Trial Locations (1)

53792

University of Wisconsin, Madison